Miranda Schmalfuhs
Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
Articles
Potential Partnerships in the Obesity Muscle Targeting Program
April 14th 2025Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" mentioned in their pipeline regarding their obesity (muscle target) program may impact the development timeline or potential partnerships for the program.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Resonating with Younger Demographics While Maintaining Medical Accuracy & Sensitivity
April 9th 2025Amy Hessels, Bayer‘s vice president of marketing, talks about how to engage younger demographics and how the Your Decision campaign contributes to broader conversations about women's reproductive autonomy and healthcare access.
Effectively Cutting Through the Misinformation Noise: Bayer’s Your Decision Campaign
April 8th 2025Amy Hessels, vice president of marketing, Bayer, discusses how its Your Decision campaign tackles misinformation about reproductive health by providing the information to empower women to discuss options with healthcare providers.
Crucial Technological Advancements for Future Pandemic Preparedness and Supply Chain Stability
April 4th 2025Marcel Botha, CEO of 10XBeta, identifies the most significant technological innovations in medical device manufacturing that will be crucial for future pandemic preparedness and supply chain stability.
The Evolution of the Intersection of Technology and Law in the Bay Area
April 4th 2025Matthew Yelovich, partner at Cleary Gottlieb, discusses his transition in late-2024 from working as a federal prosecutor to a role at Cleary Gottlieb, as well as how he sees the intersection of technology and law evolving in the Bay Area.
